Memo Therapeutics AG clinical trials
Acquired by Ipsen, Jul 22, 2026 · source ↗
The registry lists 3 studies whose lead sponsor is Memo Therapeutics AG. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2025.
Before and after it joined Ipsen
- First submitted before Memo Therapeutics AG became part of Ipsen
- 3
- First submitted after Memo Therapeutics AG became part of Ipsen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Memo Therapeutics AG3 studies
Something wrong with this grouping? Tell us on the Ipsen page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Ipsen studies →
- Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant RecipientsCompletedNCT05769582Phase 2/3
Sponsor listed in the registry: Memo Therapeutics AG · First submitted before Memo Therapeutics AG became part of Ipsen
- Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.CompletedNCT05358106Phase 1
Sponsor listed in the registry: Memo Therapeutics AG · First submitted before Memo Therapeutics AG became part of Ipsen
- To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.CompletedNCT05351437Phase 1
Sponsor listed in the registry: Memo Therapeutics AG · First submitted before Memo Therapeutics AG became part of Ipsen